February 13, 2017 10:40 AM ESTUpdated 11:18 AM
News Briefing

On a shop­ping spree, Al­ler­gan bags CoolSculpt­ing tech in $2.5B buy­out; Ake­bia strikes re­search deal with J&J

Shehla Shakoor

Managing Director

• Botox-mak­er Al­ler­gan has bagged a new com­pa­ny for its med­ical aes­thet­ics port­fo­lio, pay­ing $2.47 bil­lion for Pleasan­ton, CA-based Zel­tiq Aes­thet­ics $ZLTQ. Zel­tiq made …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times